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Calhoun Cardiology Center, Department of Cell Biology, University of Connecticut Health Center,
Farmington, CT, USA
Abstract
Cardiac fibrosis is associated with most cardiac diseases. Fibrosis is an accumulation of excessive
extracellular matrix proteins (ECM) synthesized by cardiac fibroblasts and myofibroblasts.
Fibroblasts are the most prevalent cell type in the heart, comprising 75% of cardiac cells.
Myofibroblasts are hardly present in healthy normal heart tissue, but appear abundantly in
diseased hearts. Cardiac fibroblasts are activated by a variety of pathological stimuli, such as
myocardial injury, oxidative stress, mechanical stretch, and elevated autocrine-paracrine
mediators, thereby undergoing proliferation, differentiation to myofibroblasts, and production of
various cytokines and ECM proteins. A number of signaling pathways and bioactive molecules are
involved and work in concert to activate fibroblasts and myofibroblasts in the fibrogenesis
cascade. Fibroblasts and myofibroblasts are not only principal ECM producers, but also play a
central role in fibrogenesis and myocardial remodeling in fibrotic heart disease. Thus,
understanding the biological processes of cardiac fibroblasts will provide novel insights into the
underlying mechanisms of fibrosis and provide potential targets for developing anti-fibrotic drugs.
Recent studies demonstrate that Ca2+ signal is essential for fibroblast proliferation, differentiation,
and ECM-protein production. This review focuses on the recent advances in understanding
molecular mechanisms of Ca2+ signaling in cardiac fibrogenesis, and potential role of Ca2+-
permeable channels, in particular, the transient potential (TRP) channels in fibrotic heart disease.
TRP channels are highly expressed in cardiac fibroblasts. TRPM7 has been shown to be essential
in TGFβ1 mediated fibrogenesis, and TRPC3 has been demonstrated to play an essential role in
regulating fibroblast function. Thus, the Ca2+-permeable TRP channels may serve as potential
novel targets for developing anti-fibrotic drugs.
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INTRODUCTION
Fibrosis is a pathological feature common to numerous forms of heart disease, including
myocardial infarction [1] arrhythmia [2–4]; ischemic, dilated, and hypertrophic
cardiomyopathies, [5]; heart failure [6]; inflammatory heart disease [7]; and aging associated
heart disease [8]. The fibrotic heart is characterized by abnormal conduction and impaired
diastolic and systolic functions. There are two types of fibrosis, responsive and reparative
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fibrosis [3, 9, 10]. Reparative fibrosis accompanies with cardiomyocytes death and replaces
degenerating myocytes, it is therefore also referred to as replacement fibrosis. Reactive
fibrosis occurs as a reaction to changes in myocardial load or inflammation without loss of
cardiomyocytes, and results in interstitial fibrosis [3]. The initial reactive interstitial fibrosis
is an adaptive response, and can progress into the state of replacement fibrosis, characterized
by cardiomyocytes hypertrophy and necrosis [11].
Fibrosis is an accumulation of excessive extracellular matrix (ECM) proteins produced by
cardiac fibroblasts and its differentiated phenotype, myofibroblasts. Fibroblasts are
quiescent under normal conditions. In response to pathologic stimuli, such as myocardial
injury, oxidative stress, mechanical stretch, increased level of autocrine-paracrine mediators,
and inflammatory stimuli, multiple signaling pathways and various bioactive molecules act
in concert to activate cardiac fibroblasts, leading to fibroblast proliferation, migration,
differentiation to myofibroblasts, synthesis and release of cytokines and growth factors,
production of matrix metalloproteinases (MMPs), and deposition of ECM proteins, thereby
resulting in fibrosis [12, 13]. Fibroblasts and myofibroblasts are principle producers of ECM
and play a pivotal role in fibrogenesis cascades in the heart [14, 15]. Whereas fibroblasts
play an important role in supporting the structure of a normal heart by regulating
mechanical, electrical, and chemical signaling between cellular and non-cellular
components, myofibroblasts are rarely present in the normal healthy heart tissue. However,
upon injury, myofibroblasts quickly and abundantly appear at the infarct area [16].
Myofibroblasts are more motile and can produce up to twice as much collagen as fibroblasts
[17]. Cardiac myofibroblasts are responsive to proinflammatory cytokines including
necrosis factor α (TNFα), interleukin-1 (Il-1), Il-6, TGFβ; vasoactive peptide AngII, ET-1,
ANP and BNP; and hormones such as noradrenaline. Many of the functional effects of
cardiac fibroblasts under pathological conditions are mediated through differentiated
myofibroblasts [18]. Therefore, transformation of quiescent fibroblasts to active ECM-
producing myofibroblast is a key step in cardiac fibrogenesis cascades.
The important role of fibrosis in heart disease has been well known. However, despite a
relatively sophisticated understanding of the cell biological processes underlying fibrosis,
there are few effective therapies for treating fibrotic diseases [19], emphasizing the need for
new insights into the underlying mechanism of fibrosis and novel targets for developing
anti-fibrotic drugs. Recent studies have demonstrated that transient receptor potential (TRP)
channels-mediated Ca2+ signaling plays an important role in the differentiation of fibroblast
to myofibroblasts and in the fibrogenesis cascade. This review will focus on the recent
developments in understanding the role of Ca2+ signals in fibrogenesis, and the potential of
TRP channels as therapeutic targets for anti-fibrotic drug development.
FIBROSIS IN HEART DISEASE
Fibrosis represents excessive deposition of extracellular matrix (ECM) proteins. Cardiac
fibrosis is a fundamental component of the adverse structural remodeling of the heart. It is a
detrimental factor leading to abnormalities in cardiac conduction, stiffening of the
ventricular walls, reduced contractility and impaired overall heart performance, thereby
contributing to a variety of heart diseases including: hypertrophy, heart failure, and
arrhythmia [20].
Fibrosis in Ischemia Cardiomyopathy
Fibrosis plays an important role in adverse structural remodeling of the myocardium in
failing or hypertrophic hearts from ischemic cardiomyopathy (ICM) [21]. In end-stage
failing human hearts caused by chronic artery diseases, collagen accumulation in the form of
segmental, replacement, and interstitial fibrosis comprised an average 28% and 13% of the
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left and right ventricular myocardium, respectively [21]. The necrotic cardiomyocytes in the
infarct area are replaced by fibrosis and infarct scar, and the remaining viable myocardium is
corrupted by interstitial fibrosis. The infarction scar and interstitial fibrosis constitute a
major cause of ventricular remodeling, leading to impaired conduction and reduced systolic
and diastolic performance. In the infarct heart, angiotensin II (AngII) and angiotensin type 1
(AT1) receptors are progressively increased post-myocardial infarction [22]. AT1 receptors
are localized to both macrophages and myofibroblasts [22]. Increased transforming growth
factor (TGFβ1) expression and collagen type I were found at the infarct site and attributed to
the increased number of myofibroblasts found at the infarct and remote sites. In an autocrine
and paracrine manner, AngII produced by myofibroblasts up-regulates TGFβ1, which in turn
increases collagen production (Fig. 1).
Fibrosis in Dilated Cardiomyopathy
Dilated cardiomyopathy is characterized by ventricular dilation of the heart. Myocytes
damage in dilated cardiomyopathy can be caused by unknown reasons or known reasons
such as infections and drugs [5]. Extracellular matrix proteins replace the damaged
myocytes and therefore result in increased heart size. Increased interstitial levels of collagen
in the left ventricle were found in dilated cardiomyopathy in the absence of other heart
disease such as ischemia [23]. In patients with dilated cardiomyopathy, collagen type I and
III as well as the ratio of type I/type III were all elevated [24]. Moreover, plasma levels of
TGFβ1 were twice as high in patients with idiopathic dilated cardiomyopathy when
compared to controls [25]. An increase in TGFβ level in macrophages and an increased
number of macrophages were demonstrated in the heart of individuals with dilated
cardiomyopathy [26]. In animal models, altered Smad2 and Smad4 expression in rats are
associated with increased fibrosis, elevated collagen turnover and the development of dilated
cardiomyopathy [27]. The importance of fibrosis in dilated cardiomyopathy suggests that
antifibrotic approaches may provide a means for reversing dilation of the heart and systolic
dysfunction.
Fibrosis in Arrhythmia
Fibrosis is a hallmark feature of arrhythmogenic structural remodeling in atrial fibrillation
(AF) [28], the most common sustained arrhythmia in clinical practice [29]. Increased
amounts of fibrous tissue occurs in AF patients who have other identifiable cardiac diseases
[30, 31], as well as in AF patients with lone AF [30, 32]. Mice over-expressing TGF-β1
exhibit significant atrial interstitial fibrosis with normal ventricular size and histology [33,
34], suggesting that fibrosis alone can cause AF. Atrial conduction abnormalities and
enhanced susceptibility to AF occur in the absence of abnormalities in atrial action potential
properties or connexin protein distribution [34], suggesting that atrial fibrosis itself creates a
substrate for AF. In a congestive heart failure (CHF) dog model, it was also demonstrated
that fibrosis and AF substrates persist in atria of dogs that have recovered from CHF [35,
36]. Furthermore, it has been shown that the amount of fibrosis is positively correlated with
the persistence of AF [31], suggesting that atrial fibrosis results in structural remodeling to
promote AF. Thus, both animal model data and AF patient data support the notion that atrial
fibrosis itself can promote AF.
Fibrosis in Hypertensive Heart Failure
Fibrosis is a detrimental factor in heart failure. In hypertensive heart disease (HHD) [37], a
large amount of fibrous tissues have been found and the amount of fibrosis is well correlated
with the weight of the diseased hearts [38]. Fibrous tissue in the heart is composed primarily
of type I fibrillar collagen with a small amount of type III collagen [6]. In hypertensive
hearts, the tensile strength of the fibrious tissue is comparable to steel, making the
ventricular wall very stiff and difficult for passive diastolic refilling [39–43]. In animal
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models, it was found that the regression of fibrosis resulting from treatment with AngII
converting enzyme (ACE) inhibitor lisinopril was correlated with normalized left ventricular
stiffness [44]. Patients receiving lisinopril also demonstrated reduced levels of circulating
propeptide of procollagen type I and type III, the markers of type I and type III collagen
synthesis, and normalized diastolic filling as evaluated by echocardiogram [40]. This
reversal of fibrosis by pharmacological intervention indicates that anti-fibrotic treatment
may alleviate heart failure by reducing the amount of cardiac fibrosis.
Fibrosis in Inflammatory Heart Diseases
Fibrosis also plays a role in inflammatory dilated cardiomyopathy (iDCM). Heart injury
from many causes can lead to a common final pathway of pathologic remodeling and
fibrosis, promoting heart failure development. Inflammatory dilated cardiomyopathy
(iDCM) is a subtype of dilated cardiomyopathy characterized by cardiac inflammation,
progressively impaired contractility, tissue fibrosis, and ventricular dilation [7]. Cardiac
inflammation, or myocarditis, usually results from infections with various viruses (Chagas
disease), and it is often associated with autoimmune response against heart tissue antigen
[7]. In iDCM, fibrosis results as a consequence of infiltration of granulocytes, monocytes,
macrophages, dendritic cells, mast cells, and T and B lymphocytes.
Fibrosis in Aging Heart
Myocardial aging is characterized by left ventricular (LV) fibrosis leading to diastolic and
systolic dysfunction. Extensive evidence derived from both clinical and experimental studies
suggests that the aging heart undergoes fibrotic remodeling [8]. Several distinct molecular
pathways, such as reactive oxygen species (ROS), TGFβ activation, endothelin-1 and AngII
signaling, may contribute to age-dependent fibrogenesis. In addition, aging is associated
with an impaired reparative response to cardiac injury and defective activation of reparative
fibroblasts in response to growth factors. Because these reparative defects result in defective
scar formation, senescent hearts are prone to adverse dilative remodeling following
myocardial infarction [8]. Moreover, a progressive decline in circulating C-type natriuretic
peptide (CNP) is strongly associated with a reciprocal increase in fibrosis, which precedes
impairment of diastolic and systolic function [45]. Thus, a better understanding of the
pathogenesis of interstitial fibrosis is critical to developing new strategies for preventing of
adverse remodeling and heart failure in elderly patients.
In summary, fibrosis is a hallmark feature of most heart disease. However, there are few
effective therapies for fibrotic heart diseases, emphasizing the need for a better
understanding of the underlying mechanism of fibrosis.
SIGNALING PATHWAYS INVOLVED IN CARDIAC FIBROSIS
Several signaling pathways and many bioactive molecules that cause profibrotic responses
often work in concert in the fibrogenesis cascades [46]. There are at least three well-known
common interrelated pathways involved in fibrosis including the rennin-angiotensin system,
TGFβ1, and oxidative stress pathway. The rennin-angiotensin system plays a central role in
cardiac structural remodeling and in the development of myocardial fibrosis in several
disease states including CHF [47], myocardial infarction [48], and cardiomyopathy [49].
ROS production is elevated by AngII and hypertension [50, 51]. In response to hypoxia,
fibroblasts differentiate to myofibroblasts [52], thereby initiating the fibrotic process. Both
AngII and oxidative stress induce collagen in vivo and in vitro. Oxidative stress also
contributes to cardiac fibrosis in the heart of diabetic rats [53]. TGFβ1 is a central bioactive
molecule in the fibrogenesis cascades. TGFβ1 is a downstream mediator of AngII, and
TGFβ1 also regulates AngII expression level. Other bioactive mediators such as PDGF,
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endothelin (ET), and connective tissue growth factor (CTGF), have also been demonstrated
to play important roles in cardiac fibrosis (Fig. 1).
AngII
The rennin-angiotensin-aldosterone system plays an important role in cardiac fibrosis in
hypertensive heart disease, CHF, myocardial infarction and cardiomyopathy [54]. AngII
level is elevated in overloaded hearts with fibrosis [55]. Increased local AngII production is
associated with myocyte apoptosis and reactive interstitial fibrosis [56]. AngII can induce
proliferation and differentiation of cardiac fibroblasts, induce ECM protein synthesis, and
decrease MMP activity and increase TIMP activity [18]. It appears that the profibrotic effect
of AngII is dependent on TGFβ1. In the absence of TGFβ1, AngII is unable to induce
cardiac hypertrophy [57]. AngII significantly up-regulates TGFβ1 expression through the
AT1 receptor in cardiac myocytes and fibroblasts [58]. TGFβ1 in turn can directly stimulate
AT1 receptor expression through TβR1 and Smad2/3/4 [59]. AngII can also exert its effects
independent of TGFβ. In cardiac fibroblasts, AngII also induces collagen synthesis through
ERK pathways [60]. Furthermore, p38 mitogen-activated kinase, JNK, and
phosphatidylinositol 3-kinase (PI3K) signaling pathways also appear to be involved in
TGFβ1-stimulated AT1 receptor expression [59]. AngII is a major component in the
fibrogenesis network (Fig. 1).
TGFβ
TGFβ plays a central role in cardiac fibrogenesis cascades. Extensive studies have
demonstrated that TGFβ is a potent activator of cardiac fibrosis [33, 57]. TGFβ is the
prototype of a large family of cytokines [61]. There are three TGFβ isoforms in mammals,
namely TGFβ1, TGFβ2 and TGFβ3 expressed in myofibroblasts, vascular smooth muscle
cells, endothelial cells, and macrophage [62]. The human TGFβ1 gene produces a 390 amino
acid propetide which is cleaved intracellularly to two identical 112 amino acid peptide
subunits joined together by a disulphide bond [63].
TGFβ1 is secreted initially as a biological inactive molecule bound to latent associated
peptides [64]. Latent TGFβ1 can be activated by cell-cell interaction, acidification, and
enzyme cleavage [63]. TGFβ1 exerts its biological function through a heteomeric receptor
complex comprising of two serine-threonine kinase receptors TβR1 and TβR2. Both TGFβ
ligand and receptors are present in cardiac myocytes and fibroblasts [65]. The TβR1 is an
activin linked kinase 5 (ALK5) which can phosphorylate Smad2 and Smad3, leading to
translocation of Smad2/3 to the nucleus, and activate transcription of target genes.
Conversely, TGFβ signaling is inhibited by Smad7. Phosphorylated Smad2 levels are
increasingly high in hypertension-induced heart failure [66]. Since Smad2/3 are weak
transcriptional factors, they work with co-activators such as AP-1, SP-1, TFE3 and p300 to
activate promoters of fibrosis associated genes such as collagen type 1 [67]. TGFβ also
activates a variety of noncanonical signaling pathways including ras/MEK/ERK, p38, and
TAK1 [68–70] (Fig. 1).
TGFβ activates TAK1/p38 signaling pathways through transcriptional factor ATF2 to
regulate cardiac fibrosis [71]. Transgenic mice over-expressing TAK1 develop hypertrophy,
interstitial fibrosis, and severe myocardial dysfunction [72]. A recent study demonstrated
that TGFβ activates the nuclear translocation of MRTA-F through Rho/ROCK signaling in
cardiac fibroblasts, inducing a subset of genes such as β-smooth muscle actin (βSMA)
expressed in myofibroblasts [73]. MRTA-A is a myocardin-related transcription factor A
(MRTF-A), a co-factor of serum response factor (SRF). Genetic deletion of MRTF-A in
mice abrogated fibrosis induced by myocardial infarction [73]. It was also demonstrated that
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Rho kinase activity is increased in cardiac fibrosis, and that Rho kinase inhibitor prevented
cardiac fibrosis in mice treated with aldosterone [74].
By activating the TGFβ1-Smad pathway and noncanonical pathways, TGFβ1 induces the
synthesis and release of extracellular matrix proteins (ECM). Meanwhile, TGFβ1 interacts
with matrix metalloproteinases (MMPs). It has been found that both MMP-2 levels and the
levels of membrane type-MMP (MT-MMP) are higher in terminally failing heart, in
concordance with when TGFβ1 expression is also increased [75]. In the myocardium of
infarcted rats, both TGFβ1 and MMP-2 were elevated [76]. TGFβ1 induced expression of
MMP-2 facilitates migration and motility of cardiac fibroblasts, which in turn leads to the
local production of ECM and increased fibrosis within the myocardium of the heart
associated with cardiac remodeling.
Endothelin (ET)
ET is a potent vasoconstrictor and plays an important role in chronic heart failure. ET is
secreted from endothelial cells. Among the three isoforms of ET, namely ET-1, ET-2, and
ET-3 [77, 78], ET-1 is the major isoform in humans, which can be produced by endothelial
cells but is also expressed by epithelial cells, bone marrow mast cells, macrophages, po-
lymorphonuclear leukocytes, cardiomyocytes, and fibroblasts [79]. ET-1 induces ECM
production and myofibroblast differentiation. TGFβ induces ET-1 via JNK, and ET-1 is a
downstream mediator of the fibrogenic response of TGFβ in normal fibroblasts [80]. AngII
can also induce ET-1 via ERK and reactive oxygen species [81] (Fig. 1).
Connective Tissue Growth Factor (CTGF)
CTGF is a matricellular protein [82] and an excellent surrogate marker for activated
fibroblasts in wound healing and in fibrosis. CTGF is also called CCN2. The name CCN is
an abbreviation derived from the main members: Cysterine-rich 61 (Cyr61/ CCN1), CTGF
(CCN2) and Nephroblastoma (Nov/CCN3) [83]. CTGF is predominantly expressed in
fibroblasts in the healthy heart, but is also secreted by myocytes in the process of cardiac
remodeling [84, 85]. CCN2 is significantly induced in cardiac myocytes by TGFβ, AngII
and ET-1 [86]. TGFβ induces CTGF expression through signaling cascades involving
Smads, Ets-1, and ras/MEK/ERK [87]. CCN2 promotes cell adhesion and enhances
adhesive signaling thereby creating an environment favorable for fibrogenic stimuli to act
[88, 89]. Although direct evidence functionally linking CCN2 to cardiac disease is scant,
CCN2 has been shown both in vitro and in vivo to cause hypertrophy of rat cardiomyocytes
[88, 90].
PDGF (Platelet-Derived Growth Factor)
PDGF comprises a family of homo- or hetero-dimeric growth factors including PDGF-AA,
PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. There are different PDGF receptors, β
and β [91]. Elevated PDGF-DD expression is observed postwounding [92]. PDGF causes
fibroblasts, neutrophils, macrophages, and smooth muscle cells to proliferate and migrate
into the wound site [93, 94]. PDGF also stimulate granulation tissue formation [93, 94], and
stimulates fibroblasts to contract on collagen matrix and differentiate into myofibroblasts in
vitro [95, 96]. In animal studies, transgenic mice expressing an active core domain of
PDGF-D develop interstitial fibrosis followed by dilated cardiomyopathy and subsequent
cardiac failure [97]. PDGF-D stimulates proliferation of interstitial fibroblasts and arterial
smooth muscle cells via PDGFR-β signaling. When PDGF-C is over-expressed in the heart,
transgenic mice exhibited cardiac fibrosis which resulted in hypertrophy in male mice and
dilated cardiomyopathy, heart failure and sudden death in female mice [98]. Over-
expression of PDGF-C also led to vascular defects which were likely caused by an up-
regulation of vascular endothelial growth factor in cardiac fibroblasts of the transgenic mice
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[98]. In the pressure-overloaded mouse hearts, infiltrated mast cells release PDGF-A,
promoting the fibrogenic process, thereby leading to atrial fibrosis and enhanced AF
susceptibility [99]. It appears that PDGF and PDGF receptor (PDGFR) are differentially
expressed in atria and ventricles. Burstein and colleagues found that PDGF and PDGF
receptor gene expression levels were much higher in normal atrium compared with ventricle.
In a congestive heart failure dog model, PDGF and PDGFR were also differentially
enhanced in atria versus ventricles [100]. The differential expression of PDGF and PDGFR
in atria and ventricles may explain the enhanced AF susceptibility in pressure-overloaded
hearts [99].
In summary, multiple signaling pathways, mediators, and cells types are involved in the
cardiac fibrogenesis cascade. However, the final common effector for different pathways is
the cardiac fibroblast (Fig. 1). Thus, understanding fibroblast biology is crucial for
developing anti-fibrotic drugs.
CARDIAC FIBROBLAST IS A KEY REGULATOR OF CARDIAC FIBROSIS
Cardiac Fibroblasts and Myofibroblasts
Although the signaling molecules involved in fibrosis are generated in various cell types,
cardiac fibroblast and myofibroblast are the major cell types which synthesize and deposit
extracellular matrix proteins (ECM). Cardiac fibroblast represents the most prevalent cell
type in the heart. Almost 75% of cardiac cells are fibroblasts. However, because of their
small cell size, fibroblasts contribute to only 10–15% of cardiac cell volume. While there is
considerable knowledge concerning the properties and functions of cardiomyocytes, much
less is known about cardiac fibroblasts. Cardiac fibroblasts are mostly known for their role
in the synthesis and remodeling of the ECM in the heart, but they are more than just matrix
producing cells. Fibroblasts are intricately involved in myocardial development [101].
Moreover, fibroblasts can sense changes in their microenvironment and react to these
changes in order to preserve organ function. Furthermore, cardiac fibroblasts can synthesize
a variety of bio-active molecules and secrete them into the surrounding interstitium, thereby
exerting autocrine/paracrine effects by not only acting on various cell types but also on the
fibroblasts themselves. The bioactive molecules synthesized by fibroblasts include TNFα,
IL-1β, IL-6, TGFβ, AngII, ET-1, ANP and BNP [18]. These molecules are synthesized and
secreted under different stimuli, and also act on different cell types. Overall, cardiac
fibroblasts contribute to the structural, mechanical, biochemical, and electrical properties of
the heart, and play a crucial role in cardiac pathophysiology [102].
Differentiation of Fibroblasts to Myofibroblasts
Fibroblasts are quiescent under normal conditions. When exposed to pathological stimuli
such as myocardial injury, oxidative stress, mechanical stretch, and inflammatory stimuli,
fibroblasts undergo phenotypic changes and differentiate to myofibroblasts. Myofibroblasts
are rarely present in normal healthy cardiac tissue [16], with the exception of the heart valve
leaflet. However, upon injury, myofibroblasts abundantly appear at the infarct area.
Myofibroblasts express α-smooth muscle action, and exhibit increased migratory,
proliferative, and secretary properties. Myofibroblasts can produce up to twice as much
collagen as their precursor fibroblasts [17]. Myofibroblasts can be differentiated from
resident fibroblasts, or fibroblasts from circulation. Irrespective of their origin,
myofibroblasts produce growth factor, cytokines, ECM proteins, and proteases. Cardiac
myofibroblasts are particularly responsive to proinflammatory cytokines including necrosis
factor β (TNFα), interleukin-1 (Il-1), Il-6, TGFβ; vasoactive peptide AngII, ET-1, ANP and
BNP; and hormones such as noradrenaline. Thus, the transformation of quiescent fibroblasts
to active matrix-producing myofibroblasts is a key step in disease progression.
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CALCIUM SIGNALING IN FIBROBLASTS IS CRUCIAL TO FIBROGENESIS
Electrophysiological Properties of Cardiac Fibroblasts
Resting membrane potential—The electrophysiological properties of cardiac fibroblast
will influence their abilities to exhibit excitation-secretion coupling, fibroblast-myocyte
coupling as well as fibroblast-fibroblast interactions. While the resting membrane potential
of cardiac myocytes is usually about −80 mV, fibroblasts have a much more positive resting
membrane potential. Using conventional intracellular sharp microelectrode recording, it was
reported that the resting membrane potential of cardiac fibroblasts in situ is between −31 and
−16 mV [103, 104]. Patch-clamp recordings in isolated rat atrial fibroblasts demonstrate that
the resting membrane potential is about −37 mV [105]. It is not fully understood which
channels determine resting membrane potential in cardiac fibroblasts. The inward rectifier
potassium current IK1 which is likely encoded by Kir 2.1 may contribute to resting
membrane potential [106]. However, IK1 currents have only been recorded in myofibroblasts
but not in fibroblasts [106]. Further investigation is required to understand the determinants
of resting membrane potential in cardiac fibroblasts.
Ion Channels in Cardiac Fibroblasts—The voltage-gated Na+ and K+ channels have
been demonstrated in cardiac fibroblasts. The transient-outward K+-current (Ito), and two
types of kinetically-distinct delayed-rectifier K+-currents have been demonstrated in rat
ventricular fibroblasts [107, 108]. Although the detailed molecular basis of these voltage-
gated K+ channel is unclear, it has been shown that Kv1.2, Kv1.4, Kv1.5, and Kv2.1 α-
subunits, but not Kv4.2 or Kv1.6 α-subunits are expressed at protein level detected by
Immunoblot analysis [108]. Li and colleagues demonstrated that there are two types of
voltage-gated Na currents in human ventricular fibroblasts, tetrodotoxin-sensitive (INa.TTX)
and TTX-resistance (INa.TTXR) Na currents [109]. The Nav1.3, Nav1.6 and Nav1.7 were
detected in those human ventricular fibroblasts. Moreover, delayed rectifier IK, Ito, Ca2+-
activated K+ current (BKCa), inward-rectifier (Kir-type), and swelling-induced Cl− current
(ICl.vol) channels are also present in these commercially available human cardiac fibroblasts
(HCF, CELL Applications Inc.) [109]. Recently, Chatelier and colleagues demonstrated that
the TTX-resistant INa (IC50 is ~ 1 μM) in isolated and cultured human atrial myofibroblasts,
but not in the freshly isolated fibroblasts [110]. This INa exhibits similar properties to that of
INa in the cardiac myocytes. The Nav1.5 α-subunit and the β1-subunit are markedly larger in
myofibroblasts than in fibroblasts, suggesting that INa in myofibroblasts is encoded by
NaV1.5 [110]. It is of great interest to understand the potential role of INa in fibroblast
biology and in fibrogenesis cascade. For the non-voltage gated K+ channels, the KATP
channel has been reported in mouse cardiac fibroblasts, and it is likely to be encoded by
SUR2/Kir6.1 [111]. Whereas the function of INa is unclear, it has been shown that changes
of resting membrane potential by manipulating IK1 current amplitude in rat ventricular
fibroblasts influences myofibroblast proliferation [106]. Moreover, activation of IKATP in
mouse cardiac fibroblasts results in an increase in cell proliferation and a decrease in IL-6
secretion [112]. The IKATP is also activated by sphingosine-1-phosphate (S1P) through S1P
receptor 3 (S1P3R), resulting in cell proliferation and decreases in IL-6 and collagen
secretions [111]. In human atrial fibroblasts, a voltage-gated proton (H+)-permeable current
has also been demonstrated [113], although its function is unclear. Recently, He and
colleagues demonstrate that BKCa and ICl.vol channels, but not Na+ channels, are involved in
the regulation of proliferation of cultured human cardiac fibroblasts [114]. It will be
important to determine whether and how the various ion channels in fibroblasts contribute to
basic fibroblast function, as well as to fibroblast-cardiomyocyte interactions.
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Ca2+-Signaling in Cardiac Fibroblast Functions
Ca2+ signals are essential for a variety of cellular functions including differentiation, gene
expression, cell proliferation, growth and death [115, 116]. However, unlike cardiac
myocyes, Ca2+ signaling mechanisms in cardiac fibroblasts are not fully understood. The
importance of Ca2+ in fibroblasts biology was first reported in 1996 [117]. Kiseleva and
colleagues demonstrated that Ca2+ entry through a stretch-activated channel in the plasma
membrane and Ca2+ release from the endoplasmic reticulum play key roles in the generation
of a mechanical-induced-potential (MIP) in rat cardiac fibroblasts [117]. Chelating internal
and external Ca2+ inhibits MIP. In addition, the MIP was reduced in the chronic infarct rat
hearts [118]. The stretch-induced current in fibroblasts can be blocked by a non-selective
cation channel blocker gadolinium (Gd3+) [105], suggesting that non-selective channels may
contribute to the stretch-induced currents. Furthermore, several lines of evidence suggest
that Ca2+-entry is essential for fibroblasts’ biological functions. When external Ca2+ is
chelated by EGTA, the substance P-induced proliferation of cultured rat cardiac fibroblasts
is inhibited [119, 120]. Eliminating external Ca2+ to prevent Ca2+ influx also attenuates
H2O2-induced IL-6 mRNA expression in fibroblasts [121]. In an in vivo study, mibefradil, a
non-selective L- and T-type Ca2+-channel blocker, reduced collagen production and
fibroblast differentiation in rats treated with AngII or aldosterone [122]. Taken together,
these studies indicate that Ca2+ release and Ca2+ entry through Ca2+ permeable channels are
essential for biological functions of cardiac fibroblasts.
Ca2+ Release Mechanism in Cardiac Fibroblasts
As a previous study demonstrated, ryanodine receptor (RyRs) blockers and activators can
change MIP, presumably through RyRs [117]. However, in human cardiac fibroblasts (HCF,
CELL Applications Inc.), Chen and colleagues reported that the IP3 receptors (IP3Rs) but
not the RyRs were detectable by RT-PCR [123]. Accordingly, the Ca2+ oscillations were not
influenced by ryanodine or caffeine, but were blocked by PLC blocker U73122 [123].
Moreover, Ca2+ channel blocker nifedipine and activator BayK8644 did not affect Ca2+
oscillation, suggesting that the L-type Ca2+ channels are not involved in the Ca2+ signaling
in fibroblasts. Indeed, L-type Ca2+ current has not been reported in cardiac fibroblasts so far.
In contrast, the non-specific blocker La3+ eliminated the Ca2+ oscillations. Other Ca2+
signaling components include three types of SERCA, and the plasma membrane Ca2+ pump
(PMAC) type 1, 3 and 4 detectable by RT-PCR in the human fibroblasts [123]. Chen and
colleagues also demonstrated the expression of all the TRPC channel genes and the Orai1–3
genes detected by RT-PCR [123].
TRP Channels in Cardiac Fibroblasts
Overview of TRP Channels—The first trp channel gene was cloned in Drosophila [124,
125]. A large superfamily of TRP channels containing 28 TRP channel genes has been
identified in mammals. This superfamily of TRP channel share a common structural
containing six putative transmembrane domains. Based on sequence homology, the
mammalian TRP channel superfamily can be classified into six subfamilies: TRPC, TRPV,
TRPM, TRPA, TRPP and TRPML [126–128]. The canonical TRP channel subfamily
(TRPC) contains seven members (TRPC1-7). Many of the TRPC channels are activated by
Gq-linked receptor activation, among which TRPC3 and TRPC6 can also be activated by
diaglycerol (DAG) [129]. TRPC channels often form heterotetrameric channels. For
example, TRPC1/TRPC4/TRPC5, or TRPC3/TRPC6/ TRPC7 can form functional channels
[130]. The TRPV (vanilloid) subfamily comprises six members (TRPV1-6), and several
TRPV channel are activated by noxious temperature [126–128]. The melastatin subfamily
(TRPM) includes eight TRP channels (TRPM1-8). TRPM2, TRPM6 and TRPM7 not only
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have channel function, but also contain an enzyme domain at the C-termini. The TRPP
(polycystin) and TRPML (mucolipin) families are intracellular ion-channels [131].
Many of the TRP channels are Ca2+-permeable non-selective cation channels, except that
TRPM4 and TRPM5 are monovalent cation selective channels. Most Ca2+-permeable TRP
channels are poorly-selective for Ca2+, with Ca2+/Na+ permeability ratios (PCa/PNa)
between 0.3 and 10, but TRPV5 and TRPV6 are highly Ca2+-selective, with PCa/PNa>100
[132, 133]. Unlike voltage-gated ion channels, TRP channels lack a full complement of
charged aminoacids in the S4 domain and are very weakly voltage-responsive [126, 127].
The activation mechanisms of TRP channel are highly diversified. Some TRP channels
appear to be constitutively active, whereas others are activated by Gq-linked receptor
activation, oxidative stress, changes of temperature, or an elevation of intracellular Ca2+
[126–128]. All the TRP channels appear to be regulated by PIP2 [134–137]. The unique
features of TRP channels, such as Ca2+-permeation, non-voltage gating property, and
diversified activation mechanisms such as by receptor activation, stretch and oxidative
stress, make TRPs the best candidate for mediating Ca2+ entry into cardiac fibroblasts.
TRP Channels in Cardiac Fibroblasts—Expression of TRP channels can be readily
detected by RT-PCR in the heart [138]. While many studies use cardiac tissues containing
cardiomyocytes, fibroblasts and other cell types [139], there are a number of reports that
used isolated or culture fibroblasts. In isolated rat ventricular fibroblasts, TRPC2, TRPC3,
and TRPC5 mRNA were detected by RT-PCR [140]. Nishida and colleagues reported the
presence of TRPC1, TRPC3, TRPC6, and TRPC7 in rat cardiac fibro-blasts [141]. In
cultured human cardiac fibroblasts (HCF), TRPC1, TRPC4, and TRPC6 were found to be
abundantly expressed at mRNA levels [123]. In freshly isolated human atrial fibroblasts,
several TRP channels including TRPC1, TRPC6, TRPV2, TRPV4, and TRPM7 are readily
detected by RT-PCR [142]. In mouse cardiac fibroblasts, TRPC1, TRPC3, TRPC4, TRPC6,
TRPV2, TRPV4, TRPM4, TRPM6, and TRPM7 were all detected by RT-PCR [142].
Although the expression of TRP channels can be readily detected by RT-PCR, many of
those TRP channels have not been able to be detected by electrophysiological recordings.
The first TRP channel current recorded in cardiac fibroblasts was TRPM7 [143]. TRPM7
currents recorded from rat ventricular fibroblasts were blocked by activation of Gq-linked
receptor EDG-7, a similar property to the over-expressed TRPM7 currents [143]. TRPM7 is
abundantly expressed in cardiac fibroblasts and is a major Ca2+-permeable channel in
human and mouse cardiac fibroblasts [142]. In freshly-isolated rat ventricular fibroblasts,
Rose and colleagues have demonstrated a non-selective cation current (NSCC) which can be
elicited by CNP (C-type natriuretic peptide) and cANP [140]. The cANF induced currents
were eliminated in fibroblasts pre-treated with 0.5 μg/ml PTX for 3 hour, indicating the
involvement of Gi/o protein in activation of NSCC. Moreover, the cANF induced currents
were blocked by 10 μM Gd3+, 50 μM SKF 96365 and 100 μM 2-APB. U73122 but not
U73343 also inhibited the cANF induced currents, suggesting the involvement of the PLCβ
pathway in inducing channel activation. Moreover, activation of the NSCC can also be
induced by OAG (1-oleoyl-2-acety-sn-glycerol) [140], suggesting that TRPC3, TRPC6, or
TRPC3/TRPC6 heteromers may underlie the molecular basis of the CNP activated NSCC in
rat ventricular fibroblasts [140]. In a recent elegant study, Harada and colleagues
demonstrated TRPC3 currents recorded in rat cardiac fibroblasts [144], and found that
TRPC3 regulates fibroblast function in atrial fibrillation. Other TRP channel currents which
have been recorded by electrophysiological method or Ca2+ influx approach include TRPM2
and TRPV4 [145, 146]. Rat cardiac fibroblasts exposed to hypoxia conditions for 24 hours
exhibit a linear TRPM2-like current. The TRPM2-like currents can be inhibited by
Clotrimazole with an IC50 of 0.7 μM. TRPM2 siRNA reduced the current amplitude and
TRPM2 mRNA level in fibroblasts treated with hypoxia, suggesting hypoxia up-regulates
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TRPM2 in rat cardiac fibroblasts [145]. Although the potential role of TRPM2 in fibroblasts
was not investigated, it is conceivable that TRPM2 may be involved in oxidative stress
associated fibrosis. Using 4α-12,13-didecanoate (4α-PDD) as an activator, Hatano and
colleagues recorded TRPV4 current in rat cardiac fibroblasts. The 4α-PDD induced TRPV4
current was blocked by ruthenium red, and reduced by TRPV4 siRNA [146]. It will be of
interest to investigate the potential role of TRPV4 in fibroblast biology and pathogenesis of
fibrosis
TRP CHANNELS IN CARDIAC FIBROSIS
TRPM7-Mediated Ca2+ Signal Regulates TGFβ1 Induced Fibrogenesis
TRPM7 is a unique ion channel that possesses protein kinase function [147–149]. It is
permeable to Ca2+ and Mg2+ under physiological conditions; and to Na+ under acidic
extracellular conditions. TRPM7 is constitutively active under physiological conditions and
conducts a small inward current [147, 148]. Depletion of PIP2 by stimulation of Gq-linked
receptors inactivates TRPM7 [143], whereas extracellular acidosis potentiates monovalent
inward currents of TRPM7 [150, 151]. TRPM7 plays a vital role in embryonic development
[152–155], anoxia/ischemia induced neuronal death [156, 157], Mg2+ homeostasis [153,
158], apoptosis [159], cell migration [160], breast tumor cell metastasis [161], and various
other cellular functions [162–165].
TRPM7 is ubiquitously expressed in various cells and tissues. In cardiac fibroblasts, TRPM7
is the major Ca2+-permeable channel. TRPM7 current density is up-regulated by 3~5 fold in
fibroblasts from AF patients compared with sinus rhythm patients [142]. Consistent with the
changes of TRPM7 in fibroblasts, TRPM7 is also up-regulated in cardiac myocytes from AF
patients [166]. In AF fibroblasts, Ca2+ influx is much larger than that in control fibroblasts.
Ca2+ influx is largely diminished after TRPM7 is knocked down by shRNA. TRPM7
shRNA not only inhibits TRPM7 currents and Ca2+ influx, but also inhibits TGF-β1-induced
fibroblast proliferation, differentiation and collagen-production [142]. Moreover, TRPM7 is
also up-regulated by TGF-β1 in cultured fibroblasts. It appears that TRPM7-mediated Ca2+
signals play a pivotal role in fibroblast differentiation in human AF and mediate the
fibrogenic effect of TGF-β1. Since fibrosis is one of the major detrimental factors of AF,
and TGFβ1 is a potent promoter of fibroblast differentiation and fibrogenesis, the effects of
TRPM7 in TGFβ1 mediated fibrosis suggest that TRPM7 may serve as an effective
therapeutic target for cardiac fibrosis.
TRPC3 Regulating Cardiac Fibroblast in AF
The important role of TRPC channels in cardiac hypertrophy has been extensively studied
and has been nicely reviewed [138, 167]. It appears that TRPC1, TRPC3, TRPC4, TRPC5,
TRPC6, and TRPC7 [168] are all involved in cardiac hypertrophy [138, 167, 169]. TRPC6
is essential for the development of cardiac hypertrophy in the mouse model, and is up-
regulated in patients with heart failure [170]. Cardiac-specific expression of dominant-
negative TRPC3 attenuates cardiac hypertrophic responses to neuroendocrine agonist-
infusion or pressure-overload [171]. Both TRPC3 and TRPC6 play a role in AngII-induced
NFAT nuclear-translocation in rat cardiomyocytes [172], a crucial step in cardiac
hypertrophy[173].
While most studies about TRPC functions in the heart demonstrate that TRPC channels are
involved in Ca2+ signaling in myocytes, Harada and colleagues recently reported that
TRPC3 plays a role in regulating fibroblast function, and thereby influences AF
development. In this elegant study, Harada and colleagues demonstrated that TRPC3 is
highly expressed in freshly isolated fibroblasts, but almost diminished in differentiated
myofibroblasts [144]. TRPC3 blocker pyrazole-3 inhibited AngII-induced Ca2+ influx, and
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fibroblast proliferation and differentiation. Inhibition of TRPC3 suppressed extracellular-
signal regulated kinase (ERK)-phosphorylation, resulting in reduced fibroblast proliferation.
The Ca2+ mediated fibroblast proliferation and differentiation through ERK1/2-
phosphorylation pathway was not observed in TRPC6-mediated Ca2+ in cultured neonatal
cardiac fibroblasts [141]. Nashida and colleagues found that ERK1/2 phosphorylation was
not affected by ET-1-activated TRPC6 currents. Instead, TRPC6-mediated Ca2+ by ET1
stimulation activates NFAT, which works as a negative regulator against ET-1-induced
fibroblasts differentiation [141]. Whereas the effects of TRPC6 on fibroblasts were
evaluated in cultured neonatal fibroblasts [141], which may have contributed to the
discrepancy between these two studies, the function of TRPC3 was evaluated at multiple
levels, including cultured adult fibroblasts from rats and dog, in vivo studies, and in samples
from AF patients [144]. Harada and colleagues found that TRPC3 is up-regulated in atria
from AF patients, goats with electrically-maintained AF, and tachypacing-induced heart-
failure dogs [144]. More importantly, it was demonstrated that the TRPC3 blocker
pyrazole-3 was able to prevent the development of the AF substrate in a dog model of
electrically-maintained AF. Thus, reducing TRPC3-mediated Ca2+ is likely to reduce the
susceptibility of AF, and TRPC3 may serve as a novel potential therapeutic target for
fibrotic associated AF [144].
In summary, many TRP channels have been identified in cardiac fibroblasts. However, their
physiological and pathological functions are yet to be determined. It is likely that more TRP
channel functions in cardiac fibrogenesis will be unveiled in the future.
THERAPEUTIC IMPLICATIONS
As cardiac fibrosis is a hallmark of most cardiac pathologies, anti-fibrotic strategies are
increasingly recognized as a promising approach in the prevention and treatment of fibrotic
heart diseases. A number of therapeutic agents for cardiovascular diseases have been shown
to exert pleiotropic effects on fibroblasts that underlie some of their potential benefits on
cardiac fibrosis and myocardial remodeling. For example, ACE inhibitors and AngII
receptor blockers (ARBs) inhibit AngII induced fibroblast proliferation, differentiation,
ECM turnover, and synthesis of cytokines and growth factors, thereby inhibiting fibrosis
[18]. The lipid lowering drugs Statin inhibits fibroblast proliferation and exerts antifibrotic
effects [174] possibly via anti-inflammatory/antioxidant actions. Pirfenidone prevents the
development of a vulnerable substrate for atrial fibrillation resulting from CHF by
suppressing atrial fibrosis [175].
The important role of TRP channels in regulating Ca2+ signals in cardiac fibroblasts
provides a new direction of therapeutic target for fibrotic heart disease. TRPM7-mediated
Ca2+ regulates fibroblast proliferation, differentiation, and ECM-protein production profiles
[142]. TRPC3 inhibitor pyrazole-3 administrated in vivo suppressed AF by reducing fibrosis
[144]. Thus, TRPM7 and TRPC3 are potential therapeutic targets for fibrotic heart disease.
Since a variety of TRP channels are also expressed in cardiac myocytes and contribute to
cardiac hypertrophy and heart failure [169], it is likely that inhibition of TRP channel-
mediated Ca2+ in cardiac myocytes not only produces a protective effect on myocytes, but
also may attenuate replacement fibrosis triggered by cardiomyocyte death. Given the unique
features and diversified activation mechanisms of TRP channels, future studies may uncover
more important functions of TRP channels in cardiac fibroblasts and fibrotic heart diseases.
CONCLUSIONS
Fibrosis is a hallmark feature of a variety of heart diseases. A number of signaling pathways,
bioactive molecules, and cell types are involved in cardiac fibrogenesis cascades. Cardiac
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fibroblasts have been demonstrated as the final common effector for producing and
regulating fibrosis. The importance of Ca2+ signaling in regulating fibroblast function has
long been recognized. However, the molecules responsible for Ca2+ signaling in cardiac
fibroblasts are just being revealed. TRP channels with their unique features have emerged as
the most important ion channels in mediating Ca2+ signals in cardiac fibroblasts. In the past
couple of years, TRPC3 and TRPM7 have been demonstrated to be potential novel targets
for cardiac fibrogenesis. Future studies will uncover more mechanistic insights and
therapeutic potentials of TRP channels in fibrosis associated heart disease.
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Fig. (1).
Schematic diagram illustrating cardiac fibrogenesis cascade. Multiple signaling pathways
and bioactive molecules can activate cardiac fibroblasts, leading to deposition of ECM-
proteins and formation of fibrosis. Both canonical and noncanonical TGFβ pathways
contribute to fibrogenesis. Cardiac fibrosis is associated with various forms of heart diseases
including cardiomyopathy, heart failure, and arrhythmia.
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Fig. (2).
Ion channels in the cardiac fibroblasts. A. Summary of ion channels expressed in cardiac
fibroblasts. The TRP channel mediated-Ca2+ and Ca2+ released from ER contribute to Ca2+
homeostasis, which regulates fibroblast function under normal and pathological conditions.
Ca2+-entry from TRP channels will be largely influenced by the cell membrane potential
which is controlled by various K+ channel activities. B. A representative recording of
TRPM7 from cardiac fibroblasts.
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